How Colorectal Cancer Responds to CPT-11 Treatment
Author Information
Author(s): Bras-Gonçalves R A, Rosty C, Laurent-Puig P, Soulié P, Dutrillaux B, Poupon M-F
Primary Institution: Institut Curie
Hypothesis
The study investigates how microsatellite instability and p53 status affect the sensitivity of colorectal cancers to CPT-11.
Conclusion
The study found that colorectal cancers with microsatellite instability are more sensitive to CPT-11, while those with mutated p53 show a poorer response.
Supporting Evidence
- Colorectal cancer xenografts were tested for their response to CPT-11.
- Xenografts with functional p53 were more responsive to treatment.
- MSI+ colorectal cancers showed better sensitivity to CPT-11 compared to MSI- cancers.
Takeaway
Some types of colorectal cancer respond better to a specific treatment called CPT-11, especially if they have certain genetic features.
Methodology
The study used a panel of nine colorectal cancer xenografts in nude mice to assess their response to CPT-11 treatment.
Limitations
The study's findings may not be generalizable beyond the specific xenografts tested.
Participant Demographics
The study involved human colorectal cancer samples, but specific demographic details were not provided.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website